How Atlas Helps Pharma and Medical Device Companies With FDA Inspections

FDA inspections decide whether pharma and medical device companies can keep selling their products. Quality teams have to navigate evolving CFR requirements, study past inspection patterns, and close compliance gaps before investigators walk in. Atlas is the FDA inspection and enforcement intelligence platform built for exactly that work.

The Challenge Quality Teams Face

FDA inspections can lead to various outcomes, including 483 observations, warning letters, or even more severe enforcement actions. Companies must stay ahead by understanding:

• What common issues do FDA investigators flag?
• Trends in regulatory focus areas
• How specific investigators approach compliance assessments

Without proper data and insights, teams may struggle to prepare effectively, increasing the risk of compliance issues and delays.

How Atlas Makes a Difference

Atlas is designed to give pharma and medical device companies the intelligence they need to approach FDA inspections with confidence. Here's how:

1. Data-Driven Insights from FDA Reports

Atlas continuously compiles and analyzes FDA inspection and enforcement data, including 483 observations, CFR citations, and warning letters. With this information, companies can:

• Identify recurring compliance issues across the industry
• Learn from past inspection findings to strengthen their quality systems
• Benchmark against competitors and industry standards

2. Investigator-Specific Intelligence

Not all FDA investigators focus on the same areas, and their approach can vary. Atlas provides profiles of FDA investigators, detailing:

• Their inspection history
• Commonly cited regulations
• Patterns in their findings

Atlas

See what the FDA knows about your next investigator.

30 minutes with the founder. No pitch deck.

See it live

With this knowledge, companies can better anticipate what an investigator may prioritize, ensuring they are well-prepared in advance.

3. AI Copilot

Atlas's AI copilot turns dense regulatory language into actionable answers. Ask natural-language questions about any investigator, observation, or CFR code, in any language, and get:

• Summaries of 483s, EIRs, and warning letters in any language, with color-coded primary, secondary, and tertiary issue breakdowns.
• CAPA starting points grounded in how similar observations were resolved at peer companies.
• Trend views showing how a specific investigator's focus areas or a CFR code's citation pattern have shifted year over year.

4. Fresh Data

Inspection data typically arrives on Atlas within a business week of an inspection occurring, through proprietary market intelligence, before it appears on the FDA website. Quality teams get email or WhatsApp alerts on:

• Newly issued 483s and warning letters tied to their suppliers, peers, or monitored investigators
• Shifts in enforcement priorities
• Emerging concerns affecting specific sectors or CFR codes

5. Custom Analytics

Atlas builds custom analytics rapidly for your exact use case, at no extra cost. Predetermined reports are the legacy model. Quality teams typically ask for:

• Supplier risk dashboards covering top 200 external manufacturers
• Peer comparisons by site type (API, sterile injectable, formulation)
• Investigator-specific focus-area trackers
• CFR code citation trend views

Why Atlas

Three differentiators vs. the legacy alternative:

1. Fresher data through proprietary market intelligence, typically within a business week.
2. More customizable with a responsive engineering team that ships custom analytics rapidly.
3. More accessible as named user annual subscription licenses, a fraction of enterprise pricing.

Built by ex-Google engineers. Activates with a click, no implementation. Direct engineering support: feature requests go to the people who build the product.

Want to see how Atlas fits your situation? Book a demo.